MX2017013453A - Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica. - Google Patents

Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.

Info

Publication number
MX2017013453A
MX2017013453A MX2017013453A MX2017013453A MX2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A MX 2017013453 A MX2017013453 A MX 2017013453A
Authority
MX
Mexico
Prior art keywords
dioxido
thiazine
methanone
benzo
hydroxy
Prior art date
Application number
MX2017013453A
Other languages
English (en)
Inventor
Le Grand Bruno
Lamothe Marie
Junquero Didier
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2017013453A publication Critical patent/MX2017013453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La presente invención se refiere a (4-hidroxi-2-metil-1,1-dioxido- 2H-benzo[e] [1,2] tiazin-3-il) (naftalen-2- il) metanona o una de las sales farmacéuticamente aceptables de la misma, para su uso en la prevención y/o el tratamiento de la esteatosis hepática, incluyendo la esteatohepatitis no alcohólica o una de las complicaciones de la misma.
MX2017013453A 2015-04-21 2016-04-20 Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica. MX2017013453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1553574A FR3035326B1 (fr) 2015-04-21 2015-04-21 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
PCT/EP2016/058760 WO2016169983A1 (fr) 2015-04-21 2016-04-20 Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique

Publications (1)

Publication Number Publication Date
MX2017013453A true MX2017013453A (es) 2017-12-07

Family

ID=53484018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013453A MX2017013453A (es) 2015-04-21 2016-04-20 Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.

Country Status (12)

Country Link
US (1) US20180140609A1 (es)
EP (1) EP3285774B1 (es)
JP (1) JP2018513175A (es)
KR (1) KR20170139030A (es)
CN (1) CN107530355A (es)
AU (1) AU2016251601A1 (es)
BR (1) BR112017021586A2 (es)
CA (1) CA2981933A1 (es)
FR (1) FR3035326B1 (es)
MX (1) MX2017013453A (es)
RU (1) RU2017137262A (es)
WO (1) WO2016169983A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
RU2706026C1 (ru) * 2018-12-28 2019-11-13 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体
FR2942797B1 (fr) * 2009-03-03 2011-04-29 Pf Medicament Derives de benzothiazines, leur preparation et leur application a titre de medicaments
KR101134447B1 (ko) * 2009-11-30 2012-04-10 에스케이 주식회사 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
JP2011213685A (ja) * 2010-04-01 2011-10-27 Kowa Co ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤
EP2563780B1 (en) * 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
ES2617215T3 (es) * 2011-04-19 2017-06-15 Daiichi Sankyo Company, Limited Derivado de tetrahirotiazepina

Also Published As

Publication number Publication date
JP2018513175A (ja) 2018-05-24
FR3035326B1 (fr) 2017-05-12
EP3285774B1 (fr) 2020-01-08
FR3035326A1 (fr) 2016-10-28
CA2981933A1 (fr) 2016-10-27
WO2016169983A1 (fr) 2016-10-27
RU2017137262A3 (es) 2019-09-30
AU2016251601A1 (en) 2017-11-30
KR20170139030A (ko) 2017-12-18
BR112017021586A2 (pt) 2018-07-03
EP3285774A1 (fr) 2018-02-28
CN107530355A (zh) 2018-01-02
US20180140609A1 (en) 2018-05-24
RU2017137262A (ru) 2019-05-21

Similar Documents

Publication Publication Date Title
PH12017502107A1 (en) Triazole agonists of the apj receptor
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
NZ724250A (en) Human plasma kallikrein inhibitors
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
EP3603636A4 (en) COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MX2015000618A (es) Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
PH12016501751A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP3518918A4 (en) METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
IL271236A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
EP3398614A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
NZ733451A (en) Combination therapy for pulmonary hypertension
MX2017013453A (es) Uso de (4-hidroxi-2-metil-1,1-dioxido-2h-benzo [e] [1, 2] tiazin-3-il) (naftalen-2-il) metanona en la prevencion y/o tratamiento de esteatohepatitis no alcoholica.
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EP3716975A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders